Procter and Gamble finished fiscal 2026 as a company that still grows the top line but no longer grows units. Management calls it a year of foundation building. The foundation is a productivity program that funds marketing, a portfolio trim that cuts brands and roles, and a new chairman-chief executive pairing after Jon Moeller left the board. What the year did not produce is the volume recovery that would make the next two semesters look like a reacceleration rather than another priced-in slog.
Organic sales rose one percent for the year, and every bit of that gain came from price. Reported net sales reached $87 billion after a helpful currency tailwind. Core earnings advanced one percent and finished just under $7 per share, unchanged once currency is stripped out. Operating margin contracted as mix turned worse and marketing spend rose faster than sales. The cash machine still worked. Operating cash flow approached $20 billion, and more than $15 billion went back through dividends and buybacks. That combination is why the equity still trades as a quality staple. It is also why a one-percent organic print with flat volume is a problem rather than a rounding error.
The April-June quarter made the tension visible. Organic sales were unchanged, volume was flat, and Beauty was the only segment that grew units in a convincing way. Health Care volume fell as Oral-B and Crest lost ground in North America and Greater China. Guidance for the new year calls for organic growth of one to three percent and core earnings only in-line to three percent higher, after an identified drag of more than half a dollar per share from commodities, energy, freight, interest, and currency. The question the next two semesters resolve is whether volume finally shares the load with price, or whether the Thorne wellness purchase and heavier marketing are asked to do a job that household staples no longer do on their own.